TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
A Phase IB Clinical Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab With or Without Chemotherapy in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
A PHASE1 clinical study on Metastatic Squamous Cell Carcinoma and Squamous Cell Carcinoma of Head and Neck, this trial is ongoing. The trial is conducted by H. Lee Moffitt Cancer Center and Research Institute and has accumulated 9 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Jul 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lee Moffitt Cancer Center and Research Institute
- Turnstone Biologics, Corp.
For direct contact, visit the study record on ClinicalTrials.gov .